ViiV Healthcare

Established in 2009 through a unique partnership between GSK and Pfizer, the company now combines the HIV expertise of both companies and Shionogi, who joined in 2012 following a long-term collaboration on the joint development of several novel integrase inhibitors.

Our current portfolio of thirteen HIV treatments generated annual sales of £4.35 billion in 2017 providing us with the financial stability to take a sustainable, long-term view when investing in our pipeline of new medicines. Our scientists are 100% dedicated to finding new ways to limit the impact of HIV on the more than 36 million people living with the virus and understanding how best to prevent and treat the disease. Find out more about our commitment to R&D. 

Our dedicated staff of almost 700 people are located in 15 countries and three regional hubs, and we extend this geographical reach still further because of the relationship between ViiV Healthcare and GSK. We are equipped to move quickly in response to the needs of the HIV community and have launched industry-leading access initiatives to help deliver on WHO/UNAIDS goals to reach all those who need treatment. Find out more about our innovative and sustainable approach to access.

In addition, we actively support community initiatives in HIV, including the Positive Action programme, by partnering with like-minded organisations that share our ethos.